BIO comments submitted in response to a USDA-Animal and Plant Health Inspection Service request for public comment on APHIS' new strategic plan to guide the agency's work over the next five years.
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO comments submitted in response to a USDA-Animal and Plant Health Inspection Service request for public comment on APHIS' new strategic plan to guide the agency's work over the next five years.